Debate begins over who gets the coronavirus vaccine first
The addition of its adjuvant Matrix-M, a substance designed to stimulate the body’s immune response, enhanced the effect of the vaccine in the study, the company said.
the Novavax vaccine is one of the first of a handful of programs selected for U.S. funding as part of Operation Warp Speed, the White House program to accelerate access to vaccines and treatments capable of combating the disease. virus.
The story continues under the ad
Effective vaccines and treatments are seen as key to ending a pandemic that has claimed more than 695,000 lives worldwide.
[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
Novavax Research chief Gregory Glenn told Reuters the company will soon begin much larger late-stage clinical trials and could potentially glean enough data to get regulatory approvals as early as December.
Canadian researchers diagnose dinosaur cancer for the first time
Canada to publish masks guidelines for children and recommend them for children 10 years and older
The US government agreed in July to pay Novavax $ 1.6 billion to help cover the costs of testing and manufacturing the vaccine, with the goal of purchasing 100 million doses by January 2021.
Coronavirus: Tam agrees with Fauci, warns vaccine won’t be ‘silver bullet’ but there are reasons for ‘cautious optimism’
The trial, which began in late May, tested the vaccine in 106 subjects aged 18 to 59 against a placebo. Phase I of the study examined the safety of the vaccine and its ability to induce immune responses.
He tested 5 microgram and 25 microgram doses of the vaccine, with and without adjuvant.
Fauci says he’s confident coronavirus vaccine will arrive in US by 2021
The company said the second vaccination induced higher levels of side effects such as swelling and pain at the injection site, which are not considered serious, with only one participant having a fever.
The phase II portion of the study will be conducted in several countries, including the United States. It will assess the vaccine’s ability to prevent infections or reduce the severity of COVID-19, in addition to safety and immune response, in a wider range of volunteers.
Show link »